Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

The therapy is used with a renin-angiotensin system (RAS) inhibitor unless it is not tolerated or contraindicated, Sobi said.

Aspaveli is a targeted C3/C3b inhibitor that regulates excessive complement activation, a key driver of these rare kidney diseases. C3G and IC-MPGN affect about 8,000 patients in Europe. Over half progress to kidney failure within five to 10 years, the company said.

Sobi and Apellis Pharmaceuticals hold global co-development rights, the release said.

Apellis shares were 1.7% higher in premarket trading.